

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 39/00	A1	(11) International Publication Number: WO 91/0174 (43) International Publication Date: 21 February 1991 (21.02.91)
(21) International Application Number: PCT/US90/04341 (22) International Filing Date: 2 August 1990 (02.08.90) (30) Priority data: 388,684 2 August 1989 (02.08.89) US (71) Applicant: COBE LABORATORIES, INC. [US/US]; 1185 Oak Street, Lakewood, CO 80215-4407 (US). (72) Inventor: MADDOCK, Stephen, W. ; 840 South Estes Street, Lakewood, CO 80226 (US). (74) Agent: SWANSON, Barry, J.; Beaton & Swanson, 4582 South Ulster Street Parkway, Suite 403, Denver, CO 80237 (US).		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FR (European patent), GB (European patent), JP (European patent), LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHOD OF TREATMENT WITH MEDICAL AGENTS (57) Abstract A method of therapeutic or diagnostic treatment using a medical agent in which there will be beneficial effects if the level of circulating medical agent is reduced artificially faster than the reduction by the normal clearance or routes that obviate normal clearance mechanisms. The method includes the extracorporeal removal of the medical agent by passing bodily fluid from the patient over a support adapted to selectively immobilize the medical agent.		

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America

-1-

METHOD OF TREATMENT WITH MEDICAL AGENTS

Cross-Reference to Related Application

This application is a continuation-in-part of copending application Serial No. 07/388,684 filed August 2, 1989.

Field of the Invention

5 This invention relates to the treatment of a patient with medical agents or therapeutic molecules that have short-term beneficial effects, and other, particularly longer-term, adverse effects.

Background of the Invention

10 Many medical agents are administered to a patient for achieving a desired biological effect at one or more tissues. Often the therapeutic affect of the administered substance is accompanied by toxic effects. Toxic effects may be immediate or delayed, acute or
15 chronic, or any combination of these. The toxic effects may include, but are not limited to, radiation exposure, immunization to the substance, alteration of normal metabolic function, specific tissue damage, and other diverse and/or idiosyncratic symptoms.

20 Medical agents are also administered for the purpose of diagnosing diseases. The time span during which the agents are effective for this purpose are often limited. The relative effectiveness of the administered agent as a diagnostic agent can also be limited by the
25 relative specificity of targeting of that agent to specific tissues in the body. Removal of the administered substances can often enhance the effectiveness of the substance.

30 The present invention discloses a method for the treatment of a patient with a wide variety of medical agents for therapeutic or diagnostic purposes. The common element that defines the group of medical agents

-2-

included within the scope of this invention is that they all, for a variety of reasons, reach a certain point in time after the initial treatment when their continued existence in the patient's body is no longer desirable, and is generally harmful. In some cases, the circulating medical agent is toxic to the body. In other circumstances, the medical agent itself is not toxic, but the body's mechanism for clearing the agent may be harmful to the body. In many cases the agent will accumulate, in equilibrium with circulating concentrations of the agent, in certain tissues in the body. In these cases, the agent's toxicity is localized to these tissues.

The method of the present invention encompasses the treatment of a patient with a medical agent and the subsequent selective extracorporeal removal of that agent from the patient's body. Although the extracorporeal removal of agents from patients is a well-known procedure, its combination within an integrated treatment scheme has heretofore not been described.

In a treatment scheme somewhat related to the method of the present invention, there has been described a procedure that begins with the introduction of foreign proteins into the body of a patient. These foreign, or exogenous, proteins may be immunotoxins that are introduced into the patient in order to immunologically attack an undesirable element in the patient's body. In time, the presence of the exogenous protein generates, via the patient's immune system, antibodies to the exogenous proteins. The presence of the antibodies will effectively neutralize the beneficial effects of the exogenous protein.

United States Patent Nos. 4,865,841 and 4,801,449 of Balint, Jr. et al. and 4,215,688 of Terman et al. each describe a treatment procedure whereby the endogenously

-3-

produced antibodies are removed from a patient via selective extracorporeal treatment. In each of these cases, an immunoadsorption column is prepared by covalently binding a material that will selectively immobilize the endogenous protein from the blood plasma. Since the endogenous protein which is to be removed is the antibody to the originally administered exogenous protein, selective immunoadsorption can be achieved by bonding the exogenous protein to the column material. The critical distinction between the present invention and the procedures described by Balint, Jr. and Terman is that in these procedures the agent or protein being selectively extracorporeally removed from the patient is not the same agent with which the patient is being treated, but an endogenously produced material generated by the body in response to the exogenous medical agent. Also see U.S. Patent No. 4,838,852 of Edelson et al for a related system.

In U.S. Patent Nos. 4,375,414, 4,620,977, 4,834,973 and 4,813,924 of Strahilevitz there is a described a procedure for the extracorporeal removal of psychoactive drugs from the blood stream. Again, immunoadsorption columns are described which will selectively remove the target drug from the blood stream in an extracorporeal manner. Although this procedure involves the extracorporeal removal of exogenous materials from a patient, it is not in any way part of an integrated treatment or diagnostic method. It is assumed that these methods are directed to the rescue of patients who have taken potentially harmful quantities of these non-therapeutic and non-diagnostic drugs.

United States Patent Nos. 4,824,432, 4,605,394, and 4,362,155 of Skurkovich et al. describe methods for the treatment of pathological conditions connected with the production of interferons which destroy the immune

-4-

system. In one embodiment, the endogenously produced interferons are removed by extracorporeal perfusion of a patient's blood. Again, these disclosures do not relate to an integrated treatment where medical agents are administered to a patient for therapeutic or diagnostic purposes and then removed from the patient by selective extracorporeal means in order to prevent harmful effects to the patient caused by the long-term presence of the exogenous agent. Also see U.S. Patent No. 4,925,920 of Mannick et al.

In U.S. Patent No. 4,800,016 of Yang, an extracorporeal system for the treatment of blood is described. The invention of the Yang patent is employed in medical procedures where blood is processed in an extracorporeal device, such as an artificial kidney or heart-lung machine, and the blood is heparinized to prevent clotting within the channels of the extracorporeal device. Traditionally, after heparin-containing blood has been treated in such extracorporeal devices protamine is added to the blood prior to its reintroduction into the body to negate the anti-coagulating effects of the heparin. In the Yang method, the heparin is selectively eliminated from the blood stream by passing it through a support that contains covalently-bonded protamine. By this means the heparin is actually removed from the bloodstream rather than just having its effects negated.

Yang differs from the present invention in that the heparin is not administered to a patient, but is merely part of the extracorporeal treatment of the patient's blood. The heparin does not provide a therapeutic or diagnostic benefit to the patient, but merely acts to facilitate the already extracorporeal blood supply treatment. A analogous method is described in U.S. Patent No. 4,863,611 of Bernstein, et al.,

-5-

wherein heparinase, immobilized on agarose beads, is used to remove the heparin from the blood prior to its reintroduction into the patient.

5 The immobilization of immunochemicals for use in selective separation procedures is well known. Methods for the preparation of cellulose or agarose supports that contain covalently bonded molecules, such as antibodies, are commercially available. These immobilized materials have occasionally been used in extracorporeal systems for
10 the removal of specific materials from blood plasma. See, for example, U.S. Patent No. 4,846,786 of Freed et al.

 A related technology is described in U.S. Patent No. 4,877,599 of Lees. Lees describes a method for the
15 detection of vascular disease by administering to a patient a conjugate diagnostic reagent. The conjugate reagent includes a target-seeking biologically active molecule and labelling means for extracorporeal detection. The method does not include the
20 extracorporeal removal of the administered reagent.

 In a similar scheme, U.S. Patent No. 4,863,713 of Goodwin et al. describes a system for localizing a diagnostic or therapeutic agent to an internal target site. The system includes an epitopic compound, a
25 binding protein that will direct the compound, and a clearing agent which will form a protein aggregate which is readily cleared from the patient's blood.

 Extracorporeal systems for the treatment of bodily fluids are well known. In general, blood is removed from
30 the patient and separated into plasma and blood concentrate streams. Extracorporeal treatment is almost always more effective when treating the plasma stream. After chemical modification or treatment is performed, the blood is returned to the patient.

35 There are several instances where the optimal

-6-

treatment of a patient with a medical agent for therapeutic or diagnostic procedures would include artificial or extracorporeal rescue. Nearly all administered medical agents will ultimately be cleared from the body. Generally, compounds are cleared by the functions of the liver, spleen and kidneys and the reticuloendothelial system. However, clearance can also involve immunological immobilization and degradation. Some medical agents also will accumulate in certain tissues in the body for relatively long periods of time. This invention encompasses treatments with therapeutic or diagnostic agents wherein it would be desirable to remove or drastically diminish the amount of such agents from the body before the agents would be cleared by the body under normal circumstances.

One example of a suitable medical agent system is the administration of radiolabeled antibodies to cancer patients for the purpose of diagnosing tumors and/or for therapeutic treatment of tumors. The treatments involve injection of a radiolabeled monoclonal anti-tumor antibody which has a binding specificity for molecules primarily restricted to tumor cells.

Conventional radiation therapy is a highly effective modality in the treatment of cancer. One of the severe limitations of the procedure is normal tissue tolerance to the radiation. In particular, bone marrow toxicity is the limiting factor in determining radiation dosages. In recent years, advances have been made so that it is now possible to design and create tumor-specific or tumor-related antibodies that are labeled with a radioactive substance such as ^{131}I . See, for example, Maners et al., Annals of Clinical and Laboratory Science, 1988, Vol. 18, pp. 53-57.

Several ^{131}I labeled antibodies have been prepared in attempts to maximize the localization of the

-7-

radioactive material at the tumor site. Obviously, this procedure can be valuable for both therapeutic and diagnostic purposes.

For either purpose, the treatment of cancer patients with radiolabeled antibodies has been plagued by several problems. Foremost among these problems is the lack of specificity of the antibodies to the tumor. While a significant amount of the monoclonal antibody is localized at tumor cells, the amount of monoclonal antibody localized is usually only a small percentage of the total administered dose. A large amount of monoclonal antibody will, therefore, localize to the lungs, liver, spleen and bladder as well as to other organs, or exist in the circulation system until cleared by natural mechanisms.

Improved localization would greatly improve the treatment of cancer with monoclonal antibodies for two reasons: 1) It would allow an improved signal-to-noise ratio which would allow better imaging of some tumors and recognition of previously undetected tumors; and 2) It would allow a decrease in the total body irradiation and/or a decrease in a specific organ irradiation which occurs as an undesired result of the unbound or circulating monoclonal antibody.

Tumor site localization could be artificially improved by a procedure that would eliminate "circulating" monoclonal antibodies from a patient prior to the normal clearance. Advances in the development of radiolabeled delivery agents have often focused on increasing the lifetime of the agent in the patient in order to assure that the agent is given sufficient time to reach its desired location. In engineered agents which have greatly increased circulating half-lives, the ability to remove the agent from the blood stream would be even more critical.

-8-

A variety of strategies to improve tumor localization of injected labeled monoclonal antibodies have been attempted. In Sharkey et al., Cancer Research, 1988, Vol. 48, pp. 2005-2009, the authors state:

5 Radiolabeled antibodies have proven their usefulness in the early detection of cancer by external scintigraphic imaging . . . However a
10 major problem of radiolabeled immunodetection is the persistence of high levels of blood pooled radioactivity that increases the difficulty in identifying specific antibody accretion in tumor.

Attempts at resolving this problem are described, for example, in the following additional references:
15 Wahl et al., Nucl. Med. Biol. 1987, Vol. 14, pp. 661-615; Wahl et al., Cancer Immunol. Immuno. Ther., 1988, Vol. 26, pp. 187-201; Begent et al.; The Lance, Oct. 2, 1982; Spies et al., Seminars in Nuclear Med., 1987, Vol. 17,
20 pp. 267-272; Paganelli et al., Int. J. Cancer: Supplement 2, 1988, pp. 121-125; Meeker et al., Blood, 1985, Vol. 65, pp. 1349-1363; Vacca et al., Cancer, 1988, Vol. 61, pp. 58-67; and Munz et al., J. Nucl. Med., 1986, Vol. 27, pp. 1739-1745.

25 The therapeutic and diagnostic uses of radiolabeled monoclonal antibodies in cancer treatment is just one example of a medical agent treatment where it would be desirable to eliminate circulating levels of the medical agent more rapidly than the normal body
30 clearance process. It need not be that the existence of the medical agent causes direct harm to a patient, but it may also be desirable in maximizing the therapeutic or diagnostic benefit hoped to be obtained from the medical agent or of another related or unrelated therapeutic or
35 diagnostic procedure. The present invention provides an attractive and useful approach to address all of these needs.

-9-

Summary of the Invention

5 The present invention relates to a method for removing a previously administered medical agent from a patient by passing the patient's bodily fluid containing the medical agent extracorporeally through a device which will selectively remove that medical agent from the bodily fluid. The treated bodily fluid, substantially depleted of the medical agent, is then returned to the
10 patient.

In the preferred embodiment of the invention, the extracorporeal treatment is done in a continuous and on-line procedure rather than as a batch or bolus treatment process. Such continuous treatment is quicker,
15 eliminates fluid balancing problems, and provides for the elimination of medical agents that are concentrated in body tissues but are in equilibrium with circulating levels of the agent.

The method incorporates the entire treatment
20 procedure including the administration of the medical agent, and the subsequent selective extracorporeal elimination of the medical agent at a predetermined time after administration.

In one embodiment of the invention, the medical
25 agent is a radiolabeled material that is designed to localize at or near tumor cells in a patient's body. The treatment may be performed for either therapeutic or diagnostic purposes. When used for therapeutic procedures, the radiolabeled material will irradiate the
30 associated tumor cells to destroy or prevent growth of the tumors. When used for diagnostic procedures, the radiolabeled materials may be used for imaging tumors.

At a predetermined time after administration of the radiolabeled material or at a predetermined blood
35 level concentration, the patient's plasma is

-10-

extracorporeally passed over or through a support material. The support material will be treated so that covalently bound to the support will be some material that will act to adsorb, adsorb, immobilize, complex or in some other manner prevent passage of the radiolabeled material through the support material. The treated plasma is then returned to the patient significantly reduced in the radiolabeled material. In general, extracorporeal treatment will begin after administration of the radiolabeled material, and after substantial localization of the material to the tumor has occurred.

In a preferred embodiment, the radiolabeled material is an anti-tumor monoclonal antibody. The extracorporeal treatment will then involve passing the patient's serum through a support that has been treated to contain an antigen to the antibody. In one variant of this embodiment, the support will have an anti-species antibody covalently bound to the support material, and the monoclonal antibody will act as the antigen and be immobilized on the support bed.

In another embodiment of the invention, the medical agent is a naturally occurring compound such as an enzyme or a cytokine that is being administered for therapeutic or diagnostic purposes. In another embodiment, the medical agent is a non-naturally occurring compound or drug that is being administered for therapeutic or diagnostic purposes. Central to each embodiment of the invention is the improvement in efficacy or safety of the therapeutic or diagnostic procedure that can be gained by reducing circulating levels of the medical agent more rapidly than would occur by natural clearance of the agent via bodily systems. The safety benefits gained may be in the ability to alleviate the need for normal clearance, for example, when the circulating levels of the medical agent are not

-11-

harmful, but clearance is toxic to the tissues involved in elimination, such as the kidney or liver. An example of improved efficacy is the situation where a diagnostic procedure is enhanced by elimination of circulating levels of a medical agent. Efficacy may also be found in therapeutic procedures where the elimination of circulating levels of an agent reduces non-specific toxicity and thus allows for the administration of larger doses of the beneficial medical agent.

Brief Description of the Drawing

The Figure shows a schematic pathway for the utilization of the method of the present invention.

Description of the Preferred Embodiments

Reference will now be made in detail to the presently preferred embodiments of the invention, which, together with the following examples, serve to explain the principles of the invention.

The present invention relates to a method of treatment which comprises administering to a living being a therapeutic or diagnostic agent and thereafter extracorporeally removing a portion of said agent or a derivative thereof by passing body fluid over a chemical material adapted to selectively immobilize the agent.

The term "extracorporeal" refers to a process that occurs outside of the body of the living being that is treated. Of course, to the extent that it would be possible to treat bodily fluids as described herein--to immobilize the medical agent--within a device held physically within the body, it would also be within the scope of this invention.

The extracorporeal treatment of the present invention may be continuous, on-line treatment of the body fluid, or the treatment of one or more batch or

-12-

bolus portions of the body fluid. In the preferred embodiment of the invention the treatment will be performed in a continuous or on-line manner as described below.

5 Therapeutic agents and diagnostic agents are referred to herein collectively as medical agents. A therapeutic agent is a medical agent administered to a patient in order to achieve an active beneficial effect on the well-being of the patient or to retard or
10 eliminate the detrimental effects of a disease, injury, foreign invasion or the administration of other medical agents. A diagnostic agent is a medical agent that is employed to identify or quantify the extent of a medical abnormality or to assess the status of a general or
15 specific physical trait of a patient or of the state of a specific bodily tissue or organ.

 The medical agents of the present invention may be administered alone or as part of a multipart therapeutic or diagnostic procedure. The medical agent need not be
20 the agent that directly causes the therapeutic or diagnostic benefits of the procedure utilized.

 In the preferred embodiment of the invention, the method is to be performed on vertebrate animals. In a more preferred embodiment, the living beings of the
25 invention are mammals, and in the most preferred embodiment, the living beings to be treated according to the method of this invention are human beings. Throughout this specification, the term "patient" is used interchangeably with living being.

30 Bodily fluids that are included and considered to be within the scope of this invention are, without limitation, blood, plasma, cerebral spinal fluid, and peritoneal fluid. In a preferred embodiment, the bodily fluid that is extracorporeally treated is blood. In the
35 most preferred embodiment of the invention, a patient's

-13-

blood is removed from the patient's body via venipuncture, plasma is isolated, and the plasma is passed over the chemical material or support that can selectively eliminate the medical agent from the serum.

5 Plasma may be isolated via conventional procedures that generally involve either membrane or centrifugation separations of the blood into plasma and blood concentrate streams. In another preferred embodiment, the whole blood may be passed over or in proximity to a

10 support material that will eliminate the medical agent from the blood.

The chemical material that has been adapted to selectively react with the medical agent is also referred to herein as a support or a membrane. Many materials are

15 available which can be used for this purpose. Typically, the support is modified by covalently bonding to the material of the support a chemical compound that will complex, react with, or immobilize the medical agent.

In most cases the support material will be a

20 porous gel or a porous membrane. Cellulose and agarose materials are commonly available for these purposes. For example, preactivated, amine reactive cellulose is commercially available, as is oxidized amine reactive cellulose. Other materials that could be used for

25 supports and that are susceptible to chemical modification are polyacrylonitrile, polyvinylidenedifluoride, polyvinyl alcohol, polyvinyl chloride and Nylon 66 (Immunodyne, (PALL)).

Specificity to a specific compound can usually be

30 obtained by the use of biologically derived materials. For example, the specificity that an antibody has to its specific antigen cannot generally be duplicated by other means. Therefore, in a preferred embodiment of the present invention, the selective extracorporeal removal

35 of medical agents from blood plasma utilizes the

-14-

antibody/antigen mechanism. Typically, an antibody to the medical agent is covalently bound to a support material, and passing plasma containing the medical agent over the support will serve to remove a significant portion of the medical agent from the plasma. Of course, the process works equally well when the medical agent is an antibody and the material bounded to the support is the antigen. Certain immobilized antibodies on agarose support are commercially available (for example, from Sigma Chemical Co., St. Louis, Mo.).

Materials injected and selectively removed according to the invention may be not only antibodies, but antibody fragments, engineered peptides including with structure based on desired antibody portions, and other therapeutic or diagnostic agents, or derivatives (metabolites and complexes) thereof.

Other biologically-based selective removal mechanisms are also possible, and considered within the scope of this invention. For example, attached to the support may be antibody fragments, single chain antibodies, molecular imprinting (see Ekberg *et al.*, Trends in Biotechnology, 1989, Vol. 7, pg. 92) molecular recognition units, heavy chain variable region gene antibodies (Ward *et al.*, Nature, 1989, Vol. 341, pg. 544) computer designed affinity proteins, peptides or carbohydrates, and substrate and substrate analogs (for example, labeling the medical agent with heparin, and impregnating the support with heparinase or protamine).

In one embodiment of the invention, the selective removal mechanism utilizes the hapten/hapten-antibody system. In this embodiment the medical agent may be labeled with either a hapten or a hapten antibody, and the support will contain the hapten-antibody or the hapten, respectively.

In an additional embodiment of the invention, the

-15-

selective removal mechanism utilizes the ligand/receptor system. An example would be the immobilization of avidin on the support material and the labeling of the medical agent with biotin. As used throughout this
5 specification, labeling refers to binding--either covalently or by ligands--of a moiety to the medical agent that will either assist in the therapeutic or diagnostic treatment (e.g., ^{131}I for imaging and irradiation) or will assist in the selective removal of
10 compound or both.

In additional embodiments of the invention, the medical agents may be labeled with enzymes, toxins, drugs or radioemitting elements. The particular selective removal scheme employed will depend on the nature of the
15 medical agent utilized, and it would be within the skill of one of ordinary skill in the art to determine which of the various schemes would be appropriate.

Of course, the medical agent of the present invention need not be labeled for either purposes of
20 assisting in the treatment or in the selective removal procedure. For example, the medical agent may be an antibody, a hapten, a ligand or an artificial ligand, an enzyme or some other compound which can be removed selectively from solution without labeling.

25 Descriptions of several selective separation systems of the type contemplated by this invention are described in the following citations, each of which are incorporated herein by this reference. United States Patent No. 4,865,841 of Balint, Jr. et al.; 4,846,786 of
30 Freed et al.; 4,824,432 of Skurkovich et al.; 4,813,924 of Strahilevitz; 4,800,016 of Yang; 4,725,355 of Yamamoto et al.; 4,576,928 of Tani et al.; and 4,215,688 of Terman et al.

In an alternate embodiment of the invention, the
35 selective separation system utilized is based on

-16-

physico-chemical properties of the medical agent. Such mechanisms may include size occlusion, hydrophobicity, chemical reactivity, and ionic characteristics. These selection processes are generally less selective than biologically derived mechanisms, but may be beneficial in certain embodiments and are considered to be within the scope of this invention.

The medical agents of the present invention may include soluble materials such as drugs, drug/hapten complexes, drugs labeled in the ways described above, enzymes, carbohydrates, antibodies, cytokines, biological response modifier's, glycoproteins, lipids/glycolipids, proteolipids, hormones and proteins. Partially soluble materials may also be medical agents, such as large protein complexes, liposomes, carbohydrate complexes, and inorganic complexes. Any of these compounds may be labeled either for removal purposes or for therapeutic/diagnostic purposes or may be used in their original state without additional labeling.

According to the present invention, medical agents are administered to a patient and then extracorporeally removed prior to normal clearance of the agent from the body. There are two general reasons why premature "rescue" from the medical agent may be required. First, the medical agent is beneficial to specific tissues in the body but is harmful to normal bodily tissues. This can be either acute or chronic danger, and it can be either short or long term. The harmful effect may be associated with the clearance process, or it may be associated with high circulating levels of the agent. Second, the continued presence of the medical agent in the bodily fluid may obstruct or render less effective another treatment or diagnostic action of the medical agent or another related or unrelated therapeutic or diagnostic procedure. An example of this is when the

-17-

medical agent contains a radioactive label for imaging purposes. Once the tumor-specific material has accumulated at or near tumor tissue, the circulating agent can be removed from the blood stream to help clarify the image by the reduction of background. For therapeutic uses of these materials, the removal of the agent from the blood stream will allow for lower general body toxicity and can, in turn, allow for the use of higher doses of the medical agent and greater efficacy of treatment. The method of the present invention will also allow patients to fall within allowed radiation limits at earlier times for association with other individuals.

The method of the present invention has numerous advantages over other potential treatment schemes. The extracorporeal treatment can be done in a closed circuit so there will be no fluid balance issues. Agent selectivity for many systems generally is found to be excellent. In the system described in Example 1, the column is able to remove 80% of the medical agent after treatment of three plasma volumes and 90% after treatment of six plasma volumes. (A single plasma volume may be treated in about .5 to 1.5 hours.) Again, utilizing the system described in Example 1, after extracorporeal treatment very little blood perturbation is seen. CBC and chemistry panel of the blood remain unchanged, and less than 0.08% of human plasma proteins were removed non-specifically.

The present invention may be useful in those situations where a medical agent concentrates in a particular body tissue, and its presence in the body tissue is toxic. If the agent in the tissue is in equilibrium with the agent in a bodily fluid, treatment of the body fluid can "drive" the agent out of the tissue material.

In another embodiment of the invention, the

-18-

medical agent may be an enzyme or catalatic antibody which is administered to the patient for the purpose of producing within the body an agent that acts as the therapeutic or diagnostic vehicle. Catalytic antibodies are described in Iverson et al., 1989, Science, Vol. 243, pp. 1184-1187.

In one preferred embodiment of the invention, the medical agent is a radiolabeled anti-tumor material. The anti-tumor material may be administered for either therapeutic or diagnostic purposes. In either mode, the agent is designed to selectively enrich the area adjacent to any tumors in the body relative to the rest of the body. When used therapeutically, the proximal radio-ligand will tend to destroy or impede the growth of the tumor. The concentration gradient of the agent in the vicinity of tumors allows for imaging of tumors. Such anti-tumor agents need not be radiolabeled. For example, the anti-tumor agents may include cell cytolysis factors that will destroy associated tumor cells, or they could be a bispecific antibody that binds a separately administered medical agent.

In the preferred embodiment of the invention the radiolabeled anti-tumor agent is a monoclonal antibody. Descriptions of a variety of such radiolabeled monoclonal antibodies can be found in the following references, each of which is incorporated herein by this reference: Maners et al., 1988 Annals of Clinical and Laboratory Science, Vol. 18, 53-57; Ranade, 1989 J. Clinical Pharmacol., Vol. 29, 873-884; Sands, 1990 Cancer Research (Suppl.) Vol. 50, 809s-813s.

A preferred separation mechanism would involve an anti-species antibody that would immobilize the labeled anti-tumor monoclonal antibody utilized. For example, and as shown in Examples 1 and 2, the monoclonal antibody is mouse HMFG (human milk fat globulin) labeled with ¹³¹I,

-19-

and goat anti-mouse antibody is covalently bound to a cellulose support material.

In an additional preferred embodiment of the present invention, a radiolabeled humanized chimera antibody is the medical agent, as described in Morrison et al., Important Advances in Oncology, 1990, pp. 3-18; Colcher et al., Cancer Research, 1989, Vol. 49, pp. 1738-45, incorporated herein by reference. As seen in Example 3, an anti-idiotypic antibody is immobilized on a cellulose wafer, and extracorporeal treatment is achieved.

In a further embodiment a immunoadsorption column is prepared by treatment with a hapten, benzyl diethylenetriamine pentacetic acid diamino ethane, and a radiolabeled anti-tumor anti-hapten bivalent humanized chimeric antibody is the medical agent.

The present invention has broad scope and encompasses a wide variety of applications. Based on the disclosure made herein and the knowledge of one of ordinary skill in the art, the present invention may be applied to nearly any treatment procedure with a medical agent that would benefit by the artificial clearance described herein.

According to the teachings herein, the method of the present invention would include the identification of a selective separation mechanism that would be appropriate for the selected medical agent. The separation mechanism may involve the use of an agent that will absorb, react or complex with the medical agent itself. However, it may also be more appropriate to attach the medical agent to a label that will facilitate the removal of the medical agent from the bodily fluid.

In most cases, the dynamics of the effective treatment times and the bodies clearance rates dictate that extracorporeal removal or artificial clearance of

-20-

the medical agent will be initiated a short time after administration of the medical agent. A time/dose/response analysis of the beneficial and harmful effects of the medical agent will generally be available or can be obtained without undue experimentation. Based on this information, the timing for the initiation of the selective extracorporeal removal can be easily ascertained.

The Figure shows how the extracorporeal separation of the medical agent would be removed in a preferred embodiment of the invention. Blood is removed from the patient 10, via conduit 12. A blood pump 14 (generally peristaltic pumps are utilized), to facilitate removal of the blood and its further processing. The blood will pass through a plasma separator 16 where the blood is separated into plasma and plasm streams. The plasm stream will pass via conduit 18 into and through the support containing unit 20. At Junction 22, the plasma and blood concentrate streams will be remixed and flow via conduit 24 back into the patient. This is an example of a continuous, on-line extracorporeal removal system.

The following examples illustrate various presently preferred embodiments of the invention claimed herein. All papers and references cited in the examples that follow are specifically incorporated herein by reference.

Example 1.

A column to remove HMFG (human milk fat globulin) mouse antibodies, tagged with ^{131}I , from blood plasma is prepared as follows. Three disks formed of cellulose fibers, each disk almost 3 millimeters in thickness and almost 60 millimeters in diameter, with an average pore size of 20 microns, total weight of the three about 5

-21-

grams, are fitted in a polypropylene housing of size just large enough to accommodate the wafers, and with inlet and outlet conduits and distribution and collection zones respectfully associated therewith adjacent the wafer column. A piece of polyester scrim is placed over the cellulose fiber disk nearest the collection zone, to prevent bits of cellulose that break off the disks from getting through the column. The cellulose in the housing is then treated with a solution of sodium periodate (10 millimolar), sodium phosphate (to buffer, 0.015 molar), and sodium chloride (0.15 molar), adjusted to pH 6.0, for thirty minutes at a temperature of 4°C, generating aldehyde groups attached to the cellulose of the wafers at fiber surfaces.

The wafers are then treated with a recirculating solution of goat antimouse antibody (clinical grade, as sold by Medix Biotech, Incorporated, Foster City, California, under catalog designation V-873-03G, 1 mg antibody per milliliter of solution, at the beginning of recirculation) and sodium chloride (0.15M), adjusted to pH 7.6, for two hours at room temperature. The result is a solid state immunoaffinty column, in which the antibodies are covalently coupled in Schiff-base linkages through their protein amino groups to the aldehyde groups on the cellulose. The column is then treated, to substitute monovalent covalent linkages for the divalent, so as to be able to withstand storage, by passing through it the reducing agent sodium borohydride, in 5 millimolar solution, adjusted to pH 6.0, at room temperature, for six hours. The column now has conjugated to its cellulose about 12 milligrams of the goat antimouse antibody.

Ten milligrams of the mouse antibody above specified are injected intravenously into a patient, for radiolabeling or treating a tumor with an antigen to

-22-

which binding of the mouse antibody is specific. After twenty-four hours, blood is removed through venipuncture, plasma therein separated in a membrane separator, and the plasma routed through the column. About half of the antibody injected is circulating in the blood, and 80% of this is removed in the column in 160 minutes, with almost no loss of other protein. The plasma separator used in this experiment is as found in the Century TPE (Therapeutic Plasma Exchange) device manufacture and sold by COBE Instruments, Inc. The general fluid flow is as shown in the Figure.

Example 2.

In this example, the immunoabsorption device is constructed as in Example 1, except that the starting material for the solid matrix is a commercially available preactivated cellulose capsule which preferentially immobilizes by Schiff-base covalent linkages, proteins or molecules containing amines, which are able to undergo Schiff-base linkage reactions. This capsule is commercially available from Cuno, Inc., brand named the "Zeta Affinity 60 capsule." The method for immobilizing goat antimouse heterosera antibodies to the cellulose wafers contained in this capsule is published by the manufacturer. Goat antimouse antibodies obtained from Medix Biotech, Inc. are mobilized to this cellulose matrix using the instructions supplied by the manufacturer. 35 mg of the goat antimouse heterosera are applied to the capsule, and approximately 25 mg of the goat antimouse heterosera are covalently immobilized to the cellulose matrix using this procedure.

This immunoaffinity column is then connected to the extracorporeal circuitry as described in Example 1, for use in removing radiolabeled antibodies previously administered by injection into a person.

-23-

A mouse monoclonal antibody, which binds specifically to a protein found enriched on the surfaces of some tumor cells, Human Milk Fat Globulin (HMFG) protein, is covalently labeled with a metal chelator (such as described in U.S. Patent Nos. 4,678,667 and 4,454,106) and, further, an ^{111}In radio nucleotide is chelated to the chelator which has been conjugated to the antibody. This antibody is then injected intravenously into a patient for the purpose of localizing to the antigen sites which are found predominately on the surfaces of tumor cells in the body, enabling a gamma camera image of that tumor by imaging the ^{111}In radionuclide decay photons emitted from the body.

The portion of the monoclonal antibody which remains in circulation is then removed, in part, by the immunoadsorption treatment. The patient's blood is connected to the extracorporeal circuit by way of femoral vein catherization and blood is pumped via the extracorporeal system machine out of the body and through the plasma separator. Blood concentrate exiting the separator returns to the body from the separator and plasma exiting the separator passes through the immunoaffinity capsule, and further combines with the blood concentrate and returns to the patient's circulation. As the plasma generated in the extracorporeal circuit passes through the immunoaffinity column, the monoclonal antibodies are bound by the goat antimouse antibodies immobilized to the cellulose matrix surface. Two to three patient plasma volumes, at typically three liters per plasma volume, are processed in this way, over two to three hours, resulting in approximately 12 mg of monoclonal antibody being removed when 15 mg are present in the patient's blood at the beginning of the treatment.

Example 3.

A humanized chimera antibody is generated such as described, for example, by Lobuglio et al., Proc. Natl. Acad. Sci. U.S.A., 1989, Vol. 86, pp. 4220-24, and further radiolabeled with ^{131}I in a standard radiolabeling procedure. An anti-idiotypic antibody which binds specifically to the combining region of the humanized chimera is also constructed using methods as described, for example, by Rosen et al., AIDS Res. and Human Retroviruses, 1990, Vol. 6, pg. 40; and Hildreth et al., Molecular Immunology, 1989, Vol. 26, pp. 1155-67. The anti-idiotypic antibody is then immobilized to the cellulose wafer as described in Example 2. The methods for use and results are the same as in Example 2.

Example 4.

An immunoaffinity column is constructed by placing 60 mm diameter round disks of porous Nylon 66 membrane (available from PALL Corp., brand named "Immunodyne") which has been surface-treated to enable covalent immobilization of amines to its surface in layers one on top of another with a nylon mesh spacer between layers in a 60 mm diameter cylindrical housing, bounded on the top and bottom by end caps which allow fluids to enter the end cap, spread over the surface of the layers, pass through each layer successively, and exit through the other end cap. While in this configuration, 10 mg of a hapten, benzyl diethylenetriamine pentaacetic acid diamino ethane is passed through the membranes and covalently bound to the membranes using the membrane manufacturer's instructions. In this way, approximately 1 microgram of hapten is immobilized per square centimeter of each layer of the immobilization membrane. For 5 layers of membrane per such device, approximately 140 micrograms of hapten are immobilized.

-25-

Five mg of radiolabeled anti-hapten, anti-tumor, bivalent humanized chimeric antibody as described by Ledoussal et al., Cancer Research, 1990, Vol. 50, pp. 3445-3452; and EP applications 369576, 369566, is
5 injected into a patient for the purpose of localizing to tumor sites. The patient is immunoadsorbed as in Example 2, using the hapten immobilized immunoaffinity column just described, at 24 hours after the antibody was injected, and processing six plasma volumes over a period
10 of three hours, 90% of the anti-hapten antibody is removed.


It is to be understood that the application of the teachings of the present invention to a specific medical agent and separation system will be within the
15 capabilities of one having ordinary skill in the art in light of the teachings contained herein. Thus it will be apparent to those of ordinary skill in the art that various modifications and variations can be made in the method of the present invention. It is intended that the
20 present invention covers these modifications and variations provided they come within the scope of the appended claimed and their equivalents.

CLAIMS

1. A method of treatment which comprises administering to a living being a medical agent and thereafter extracorporeally removing said medical agent or metabolites, complexes or products thereof by passing bodily fluid over a support adapted to immobilize said agent.

5

1/1



I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(5): A61K; 39/00
U.S. CL.: 424/85.5

II. FIELDS SEARCHED

Minimum Documentation Searched *

Classification System

Classification Symbols

U.S. 424/85.8, 85.5, 88.91

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched *

APS-CAS: Immobilize, Antibody, Column

III. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No. 1 *
Y	US, A, 4,824,432 (SKURKOUICH ET AL) 25 APRIL 1989 See entire document	1
Y	US, A, 4,865,841 (BALINT, JR. ET AL) 12 SEPTEMBER 1988	1
Y	Brochemicals, Organic compounds for research and Diagnostic reagents, Sigma Chemical Co., P.O. BOX 14508, St Louis, MO 63178 USA 1989, PP 806-807	1

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"d" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search :

24 DECEMBER 1990

Date of Mailing of this International Search Report :

18 JAN 1991

International Searching Authority :

ISA/US

Signature of Authorized Officer :

RUSSELL TRAVES